{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Teo CF"],"funding":["National Institute of Diabetes and Digestive and Kidney Diseases","National Institutes of Health","National Institute of General Medical Sciences","NIGMS NIH HHS"],"pagination":["1198-1208"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5884396"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["26(11)"],"pubmed_abstract":["Previous studies utilizing PUGNAc, the most widely used β-N-acetylglucosaminidase (OGA) inhibitor to increase global O-N-acetylglucosamine (GlcNAc) levels, have reported a variety of effects including insulin resistance as a direct result of elevated O-GlcNAc levels. The notion of OGA inhibition causing insulin resistance was not replicated in studies in which elevated global O-GlcNAc levels were achieved using two other OGA inhibitors. Related to insulin action, work by others has suggested that O-GlcNAc elevation may inhibit the anti-apoptotic action of insulin. Thus, we examined the pro-survival action of insulin upon serum deprivation in the presence of PUGNAc as well as two selective OGA inhibitors (GlcNAcstatin-g and Thiamet-G), and a selective lysosomal hexosaminidase inhibitor (INJ"],"journal":["Glycobiology"],"pubmed_title":["Dissecting PUGNAc-mediated inhibition of the pro-survival action of insulin."],"pmcid":["PMC5884396"],"funding_grant_id":["P41 GM103490","P41GM103490","R01DK075069"],"pubmed_authors":["El-Karim EG","Teo CF","Wells L"],"additional_accession":[]},"is_claimable":false,"name":"Dissecting PUGNAc-mediated inhibition of the pro-survival action of insulin.","description":"Previous studies utilizing PUGNAc, the most widely used β-N-acetylglucosaminidase (OGA) inhibitor to increase global O-N-acetylglucosamine (GlcNAc) levels, have reported a variety of effects including insulin resistance as a direct result of elevated O-GlcNAc levels. The notion of OGA inhibition causing insulin resistance was not replicated in studies in which elevated global O-GlcNAc levels were achieved using two other OGA inhibitors. Related to insulin action, work by others has suggested that O-GlcNAc elevation may inhibit the anti-apoptotic action of insulin. Thus, we examined the pro-survival action of insulin upon serum deprivation in the presence of PUGNAc as well as two selective OGA inhibitors (GlcNAcstatin-g and Thiamet-G), and a selective lysosomal hexosaminidase inhibitor (INJ","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Nov","modification":"2025-04-04T19:34:24.203Z","creation":"2019-03-26T23:50:11Z"},"accession":"S-EPMC5884396","cross_references":{"pubmed":["27072814"],"doi":["10.1093/glycob/cww043"]}}